Stay Informed on Corporate Sustainability

Author: Archie Villaflores

Zymeworks has secured $250 million (€212 million) in royalty-backed financing from Royalty Pharma to strengthen its balance sheet. The transaction supports pharmaceutical manufacturing excellence operations and provides capital for strategic acquisitions through 2028.

Author: Archie Villaflores

Novo Nordisk has submitted a full reimbursement application to Ireland's Health Service Executive for obesity drug Wegovy. The assessment process strengthens pharmaceutical manufacturing excellence sector engagement with national healthcare systems and patient access frameworks.

Author: Archie Villaflores

County Galway-based Chanelle Pharma reported pretax profits increasing 51.5 per cent to €16.75 million as revenues rose 17 per cent to €223.19 million. The performance strengthens Ireland's position in generic pharmaceutical manufacturing excellence.

Author: Archie Villaflores

Danish pharmaceutical manufacturer Novo Nordisk will invest €430 million to expand its Athlone facility for tablet production of weight loss drug Wegovy. The development strengthens Ireland's pharmaceutical manufacturing excellence capabilities and creates 600 construction positions.

Author: Archie Villaflores

Strategic partnerships that unlock AI-driven discovery and acquisitions that consolidate cell therapy manufacturing drive pharmaceutical sector growth. Companies securing investment whilst acquiring clinical-stage assets demonstrate how capital deployment accelerates therapeutic development and market entry. Turning the clock back to last year's accomplishments, 'Uniphar Medtech wins Corporate Social Responsibility Programme of the Year at Pharma Industry Awards 2025' earned recognition for its Local Competitive Advantage initiative transforming local inclusion into a talent pipeline. This achievement establishes benchmarks for the 2026 awards, where strategic social investment aligned with business objectives will distinguish CSR leadership. Furthermore, 'Belfast drug discovery firm secures South Korean strategic investment' demonstrates how AI-enabled platforms attract international biotech backing through multi-omic data mining and oncology programme validation. AMPLY Discovery's partnership with Keeps Biomed strengthens Northern Ireland's pharmaceutical research capabilities whilst exploring collaboration opportunities. Meanwhile, 'Gilead Sciences acquires CAR-T specialist Arcellx for $7.8 billion' reflects how pharmaceutical majors consolidate cell therapy manufacturing through strategic acquisition of companies approaching regulatory approval. The transaction adds anito-cel to Gilead's blood cancer portfolio with FDA action anticipated by December 2026. Investment and acquisition define pharmaceutical sector momentum. Read each story to understand how strategic partnerships and manufacturing consolidation are accelerating therapeutic development.

Author: Jed Nykolle Harme

Honoured for transformative community impact in 2025, Uniphar Medtech won Corporate Social Responsibility Programme of the Year at the Pharma Industry Awards 2025, setting a benchmark for talent development as the sector looks toward 2026.

Author: Archie Villaflores

United States pharmaceutical manufacturer AbbVie will invest $380 million (€322 million) to construct two manufacturing facilities at its North Chicago campus. The plants will produce active pharmaceutical ingredients for obesity and neuroscience medications, creating 300 positions.

Author: Archie Villaflores

United States-based pharmaceutical company Gilead Sciences has agreed to acquire CAR-T specialist Arcellx for $7.8 billion (€6.6 billion). The acquisition strengthens Gilead's manufacturing excellence capabilities in cell therapy production for blood cancer treatment.

Author: Archie Villaflores

Australia's Argent BioPharma has delivered its largest commercial shipment of CannEpil to Ireland, where the epilepsy treatment is fully reimbursed under National Health Insurance. The €467,000 shipment strengthens Ireland's pharmaceutical supply chain capabilities for neurological therapies.

Author: Archie Villaflores

DHL Group is expanding its dedicated airfreight cold chain network to Ireland and seven other countries to meet pharmaceutical transport demand. The €2 billion investment strengthens temperature-controlled logistics capabilities for biologics and cell and gene therapies.